10 Best Performing NASDAQ Stocks According to Wall Street Analysts

7. Sensei Biotherapeutics Inc. (NASDAQ:SNSE)

6-Month Performance: 200.36%

Average Upside Potential: 64.20%

Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition of Faeth Therapeutics and a concurrent $200 million private placement. The company’s lead program is now PIKTOR, an all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. This new capital, combined with existing cash, is expected to fund clinical operations through major 2026 milestones, including Phase 2 data in endometrial cancer and a Phase 1b trial in breast cancer.

Financial results for the full year 2025 reflect a period of significant cost reduction and restructuring. R&D expenses dropped to $11.0 million from $18.6 million in 2024, while G&A costs fell to $11.3 million. These decreases were largely driven by lower personnel and manufacturing costs, alongside reduced spending on facilities and laboratory supplies.

The company reported a net loss of $21.1 million for 2025, an improvement over the $30.2 million loss recorded the previous year. As of December 31, 2025, Sensei Biotherapeutics Inc. (NASDAQ:SNSE) held $21.2 million in cash and marketable securities, down from $41.3 million at the end of 2024. However, the subsequent $200 million financing significantly supports the balance sheet to back the accelerated development of its oncology pipeline.

Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is a clinical-stage biotechnology company that treats cancer through multi-node inhibition of critical oncogenic pathways.